Cargando…

Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?

Detalles Bibliográficos
Autores principales: López-Medrano, Francisco, Aguado, José María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310784/
https://www.ncbi.nlm.nih.gov/pubmed/34325068
http://dx.doi.org/10.1016/j.cmi.2021.07.012
_version_ 1783728834707718144
author López-Medrano, Francisco
Aguado, José María
author_facet López-Medrano, Francisco
Aguado, José María
author_sort López-Medrano, Francisco
collection PubMed
description
format Online
Article
Text
id pubmed-8310784
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-83107842021-07-26 Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy? López-Medrano, Francisco Aguado, José María Clin Microbiol Infect Commentary European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021-10 2021-07-26 /pmc/articles/PMC8310784/ /pubmed/34325068 http://dx.doi.org/10.1016/j.cmi.2021.07.012 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
López-Medrano, Francisco
Aguado, José María
Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?
title Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?
title_full Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?
title_fullStr Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?
title_full_unstemmed Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?
title_short Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?
title_sort intravenous immunoglobulins for the treatment of the hyper-inflammatory response in covid-19. another failure of immunomodulatory therapy?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310784/
https://www.ncbi.nlm.nih.gov/pubmed/34325068
http://dx.doi.org/10.1016/j.cmi.2021.07.012
work_keys_str_mv AT lopezmedranofrancisco intravenousimmunoglobulinsforthetreatmentofthehyperinflammatoryresponseincovid19anotherfailureofimmunomodulatorytherapy
AT aguadojosemaria intravenousimmunoglobulinsforthetreatmentofthehyperinflammatoryresponseincovid19anotherfailureofimmunomodulatorytherapy